25.04

0.93% 0.23

After Hours: 25.04

Pacira Biosciences Inc (PCRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pacira Biosciences Inc stock is traded at $25.04, with a volume of 764.84K. It is up +0.93% in the last 24 hours and up +9.34% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Previous Close:

$24.81

Open:

$24.87

24h Volume:

764.84K

Relative Volume:

1.08

Market Cap:

$1.13B

Revenue:

$681.75M

Net Income/Loss:

$70.47M

P/E Ratio:

17.27

EPS:

1.45

Net Cash Flow:

$173.19M

1W Performance:

+11.79%

1M Performance:

+9.34%

6M Performance:

-5.62%

1Y Performance:

+101.94%

1-Day Range:

$24.77

$25.26

1-Week Range:

$22.38

$25.50

52-Week Range:

$12.14

$27.98

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name

Pacira Biosciences Inc

Sector

Healthcare (1161)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

650-242-8052

Address

2000 SIERRA POINT PARKWAY, BRISBANE, NJ

Employee

790

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PCRX's Discussions on Twitter

Compare PCRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCRX Pacira Biosciences Inc	25.04	1.11B	681.75M	70.47M	173.19M	1.45
ZTS Zoetis Inc	152.44	66.38B	9.39B	2.62B	2.22B	5.81
TAK Takeda Pharmaceutical Co Adr	14.77	46.20B	29.96B	957.25M	5.31B	0.304
HLN Haleon Plc Adr	9.69	42.99B	14.26B	1.98B	0	0.4347
TEVA Teva Pharmaceutical Industries Ltd Adr	17.21	19.04B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	309.72	13.63B	2.99B	1.21B	1.13B	25.06

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Upgrade	Truist	Hold → Buy
Jan-30-25	Upgrade	Truist	Sell → Hold
Aug-13-24	Downgrade	Truist	Buy → Sell
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-07-24	Resumed	JP Morgan	Overweight
Dec-20-23	Initiated	Raymond James	Outperform
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform
Jan-31-23	Resumed	Wedbush	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Jan-03-22	Resumed	JP Morgan	Overweight
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight
Apr-21-21	Resumed	JP Morgan	Neutral
Apr-09-21	Initiated	Berenberg	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform
Jul-06-20	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Nov-06-19	Initiated	BTIG Research	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-06-19	Upgrade	Mizuho	Underperform → Neutral
May-02-19	Upgrade	Stifel	Sell → Hold
Feb-01-19	Downgrade	Mizuho	Neutral → Underperform
Aug-06-18	Downgrade	BofA/Merrill	Buy → Neutral
Apr-09-18	Reiterated	H.C. Wainwright	Buy
Mar-21-18	Reiterated	Mizuho	Neutral
Feb-16-18	Downgrade	Needham	Buy → Hold
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jan-04-18	Reiterated	Canaccord Genuity	Buy
Jan-03-18	Initiated	Leerink Partners	Mkt Perform

View All

Pacira Biosciences Inc Stock (PCRX) Latest News

10:35 AM

Investors Who Lost Money with Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Should Contact the Shareholders Foundation in Connection with Lawsuit - Newswire.com

10:35 AM

07:25 AM

Can technical indicators confirm Pacira BioSciences Inc.’s reversalJuly 2025 Setups & Safe Capital Allocation Plans - Newser

07:25 AM

06:40 AM

Natixis Advisors LLC Invests $327,000 in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

06:40 AM

04:47 AM

Volatility clustering patterns for Pacira BioSciences Inc.July 2025 Rallies & AI Powered Market Entry Strategies - Newser

04:47 AM

04:26 AM

Will Pacira BioSciences Inc. stock recover after recent dropWeekly Trade Analysis & Growth Oriented Trading Recommendations - Newser

04:26 AM

03:28 AM

Advanced analytics toolkit walkthrough for Pacira BioSciences Inc.2025 Key Lessons & AI Driven Stock Price Forecasts - Newser

03:28 AM

02:53 AM

Pacira BioSciences Inc. stock trendline breakdownJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser

02:53 AM

Aug 12, 2025

Is Pacira BioSciences Inc. building a consolidation baseFree Day Trading Signals With High Precision - Newser

Aug 12, 2025

Trend analysis for Pacira BioSciences Inc. this weekLong Term Stock Growth Plan Suggestions - Newser

Aug 12, 2025

Real time alert setup for Pacira BioSciences Inc. performanceWeekly Setup Summary for Risk Controlled Trades - Newser

Aug 12, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire

Aug 12, 2025

Exit strategy if you’re trapped in Pacira BioSciences Inc.Safe Investment Ideas with Growth Upside - Newser

Aug 12, 2025

Signal strength of Pacira BioSciences Inc. stock in tech scannersSupport and Resistance Zone Summary Chart - Newser

Aug 12, 2025

Aug 11, 2025

How Pacira BioSciences Inc. stock performs during market volatilityAI Enhanced Strategy for Portfolio Growth - Newser

Aug 11, 2025

Pacira BioSciences Inc (NASDAQ: PCRX) Yet To Convince Analysts? - stocksregister.com

Aug 11, 2025

Will a bounce in Pacira BioSciences Inc. offer an exitEntry and Exit Strategy for Swing Traders - Newser

Aug 11, 2025

Detecting price anomalies in Pacira BioSciences Inc. with AIFundamental Analysis for Value Stock Selection - Newser

Aug 11, 2025

Earnings visualization tools for Pacira BioSciences Inc.Free Short Term Buy Zone Stock Alerts - Newser

Aug 11, 2025

Aug 10, 2025

Order flow analysis tools used on Pacira BioSciences Inc.Free Real Profit Trade Plan Suggestions - Newser

Aug 10, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Aug 10, 2025

Pacira announces layoffs due to efficiencies in Exparel production - MSN

Aug 10, 2025

Doma Perpetual's 5.7% Stake in Pacira Biosciences: A Catalyst for Governance Change or Strategic Alignment? - AInvest

Aug 10, 2025

Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $25.75 - Defense World

Aug 10, 2025

Aug 08, 2025

Doma Perpetual Discloses 5.7% Stake in Pacira Biosciences - MarketScreener

Aug 08, 2025

Can machine learning forecast Pacira BioSciences Inc. recoveryRisk Balanced Picks for Safer Trading - Newser

Aug 08, 2025

Pacira BioSciences, Inc. (NASDAQ:PCRX) Position Lifted by Zurcher Kantonalbank Zurich Cantonalbank - Defense World

Aug 08, 2025

Aug 07, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Aug 07, 2025

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 07, 2025

Can Pacira BioSciences Inc. rally from current levelsStrong Buy Opportunity with Volume Support - Newser

Aug 07, 2025

Aug 06, 2025

Pacira Biosciences Q2 Earnings Call Highlights Growth and Strategy Amid Challenges - AInvest

Aug 06, 2025

Pacira BioSciences Reports Q2 2025 Results: EPS of -$0.11 Misses Estimates, Revenue at $181.1 Million Below Expectations - AInvest

Aug 06, 2025

Pacira BioSciences Reports Q2 2025 Financial Results: $181.1M Revenue, Net Loss of $4.8M - AInvest

Aug 06, 2025

New Product Launches: Will They Boost Pacira BioSciences Inc. Stock in 2025Momentum Entry Alerts with Risk Control - Newser

Aug 06, 2025

Pacira Biosciences shares rise 2.09% intraday after Q2 revenue beat expectations. - AInvest

Aug 06, 2025

Pacira Biosciences Q2 Non-GAAP Earnings Fall, Revenue Rises; Updates 2025 Sales Forecast - MarketScreener

Aug 06, 2025

Pacira BioSciences Posts Strong Q2 Growth, Boosts 2025 Revenue Guidance - AInvest

Aug 06, 2025

Pacira BioSciences (PCRX) Bolsters Growth with Strategic Moves - GuruFocus

Aug 06, 2025